Full View

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Y Wang, K Johnston, E Popoff, KJ Myren… - Journal of Medical …, 2020 - Taylor & Francis
Aims Ravulizumab, engineered from eculizumab, provides sustained C5 inhibition in
atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs 2 …
被引用次数：27 相关文章

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome.

Y Wang, K Johnston, E Popoff, KJ Myren… - Journal of Medical …, 2020 - europepmc.org
Aims Ravulizumab, engineered from eculizumab, provides sustained C5 inhibition in
atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs 2 …

A US cost-minimization model comparing ravulizumab versus eculizumab for the treatment of atypical hemolytic uremic syndrome

Y Wang, K Johnston, E Popoff… - Journal of medical …, 2020 - pubmed.ncbi.nlm.nih.gov
Aims Ravulizumab, engineered from eculizumab, provides sustained C5 inhibition in
atypical hemolytic uremic syndrome (aHUS) while reducing dosing frequency (every 8 vs 2 …